# CSL leadership transition and financial performance

> Live situation record from CLSTR: https://clstr.news/situations/csl-leadership-transition-and-financial-performance
> Updated: 2026-10-26T23:30:00.000Z. Sources: 5. Developments: 2.

CSL Limited has announced the appointment of Deborah Waterhouse as Chief Executive Officer and Managing Director, effective February 1, 2027. Waterhouse, who currently serves as CEO of ViiV Healthcare and President of GSK Global Health, is the company’s first female chief executive.

The leadership change follows a period of significant financial volatility and a decline in market value. During the 2025/26 financial year, CSL reported a statutory net loss of US$2.6 billion, primarily due to writedowns in its Vifor kidney treatment and iron deficiency businesses. These divisions have faced difficulties stemming from regulatory shifts and generic competition. 

As a result of these earnings, the company’s share price dropped from approximately $310 in July 2024 to a nine-year low of roughly $90 in June 2026. CSL Chair Dr. Brian McNamee noted that the board’s decision to appoint Waterhouse was based on her capacity to “grow complex businesses, renew pipelines, and manage international partnerships.”

## Timeline

### 2026-10-26: CSL appoints new CEO following significant market value decline

CSL has appointed Deborah Waterhouse as its first female CEO following a US$2.6 billion statutory net loss and a significant decline in market value.

2 sources. https://clstr.news/cluster/csl-appoints-new-ceo-following-significant-market-value-decline

### 2026-10-21: CSL appoints Deborah Waterhouse as CEO and Managing Director

CSL Limited has named Deborah Waterhouse, current CEO of ViiV Healthcare, as its next CEO and Managing Director, effective February 2027.

4 sources. https://clstr.news/cluster/csl-appoints-deborah-waterhouse-as-ceo-and-managing-director

---
Cite as: CSL leadership transition and financial performance. CLSTR, https://clstr.news/situations/csl-leadership-transition-and-financial-performance
